U.S. Patent and Trademark Office Director Andrei Iancu urged the Federal Circuit Monday to hold off on any Arthrex-based remand in a case alleging that the PTAB’s fee model improperly encourages judges to institute America Invents Act reviews, saying judges should wait until the U.S. Supreme Court decides whether to review Arthrex…

Read this piece in its entirety at Law360.